

# UC Berkeley

## UC Berkeley Previously Published Works

### Title

Variation among hemp (*Cannabis sativus* L.) analytical testing laboratories evinces regulatory and quality control issues for the industry

### Permalink

<https://escholarship.org/uc/item/9cd2s2rk>

### Authors

Azwell, Thomas  
Ciotti, Chloe  
Adams, Arthur  
et al.

### Publication Date

2022-12-01

### DOI

10.1016/j.jarmap.2022.100434

Peer reviewed

1  
2 **Variation among hemp (*Cannabis sativus* L.) analytical testing**  
3 **laboratories evinces regulatory and quality control issues for the**  
4 **industry**

5  
6 **Thomas Azwell<sup>1</sup>, Chloe Ciotti<sup>1</sup>, Arthur Adams<sup>1</sup>, & Guido F. Pauli<sup>2</sup>**

7  
8 <sup>1</sup>Azwell Lab, College of Engineering, University of California, Berkeley, United States

9 <sup>2</sup>Pharmacognosy Institute and Department of Pharmaceutical Sciences, College of Pharmacy,  
10 University of Illinois at Chicago, United States

11  
12 **Keywords: cannabidiol, tetrahydrocannabinol, hemp regulation, USDA, THC**

13  
14 **Abstract**

15 Validated analytical testing of cannabinoid content for regulatory purposes is critical to  
16 farming high-cannabidiol (CBD) hemp (*Cannabis sativus* L.), as these methods are key to  
17 determine whether a crop is federally compliant by containing <0.3% THC or must be destroyed  
18 at the time of harvest. This report identifies the sources and extent of variation in reported  
19 cannabinoid content after flower selection and conducted a survey of ten accredited hemp  
20 regulatory testing laboratories, including one state-owned laboratory. The results indicate that total  
21 tetrahydrocannabinol (THC) content is reported inconsistently due to an insufficient  
22 standardization of sample preparation and testing methods, thus likely leading to erroneous data.  
23 This work represents the early phase of ongoing research to enhance the consistency of  
24 cannabinoid analyses of hemp flower samples as an essential tool in Cannabis crop development.

25  
26 **1. Introduction**

27 Although hemp and marijuana plants belong to the same group of three species, *Cannabis*  
28 *sativa*, *C. indica*, and *C. ruderalis*, recent agricultural legislation in the U.S. has reclassified hemp,  
29 removing it from the Schedule 1 controlled substances list and distinguishing it from marijuana by

30 using the total THC level as a threshold. These levels are limited to “a  $\Delta$ 9-tetrahydrocannabinol  
31 concentration of not more than 0.3 percent on a dry weight basis” in any part of the hemp plant  
32 and any products derived from its cultivation (USDA Agricultural Marketing Service, 2019). This  
33 definition of hemp, tied to plant chemotype rather than plant genotype, stems from a 1976  
34 taxonomical study distinguishing industrial hemp (used commonly at the time for fiber and food)  
35 from psychoactive, high-THC cultivars of (mostly) *C. sativa* marijuana (Small-Cronquist, 1976).  
36 However, hemp is known to be genetically distinguishable from marijuana because it lacks the  
37 allele coding for THCA-synthase (De Meijer et al., 2003; Sawler et al., 2015).

38         While industrial fibrous hemp remains an important crop, an increasing number of farmers  
39 are cultivating medicinal cultivars of hemp to meet consumer demand for CBD and other  
40 cannabinoid products such as cannabigerol (CBG) and cannabichromene (CBC). These products  
41 have been shown to have pharmacological activity providing purported therapeutic potential for  
42 antiepileptic, anxiolytic, antipsychotic, anti-inflammatory, and neuroprotective effects  
43 (Bridgeman-Abazia, 2017). Hemp flowers grown for medicinal use today contain up to 15% of  
44 CBD plus additional non-THC/non-CBD cannabinoids by dry weight. Depending on the growing  
45 conditions that favor cannabinoid production, these variants often approach or slightly exceed the  
46 0.3% THC limit for classification as hemp at the time of harvest—despite having no psychotropic  
47 effects compared with marijuana, which is cultivated for the production of THC at dry-weight  
48 percentages commonly in excess of 20%. In general, a level of about 1% THC is considered the  
49 threshold for cannabis to have a psychotropic effect (Small-Marcus, 2002).

50         The industry faces several challenges as it attempts to scale cultivation to meet consumer  
51 demand for cannabinoid products. For example, categorizing cultivars becomes difficult due to  
52 variation in testing protocols and discrepancies in results between testing laboratories. However,

53 these results are critical when quantifying the amount of THC in hemp flower and hemp-derived  
54 extracts, and certificates of analysis (COA) are compulsory for legal hemp harvest. In most states,  
55 hemp farmers are required to submit a request to the state 30 days before the anticipated harvesting  
56 time, so an official sampler can collect flowers from multiple plants of the same strain on the farm  
57 for compliance testing (Cal. Code Reg., 2021).

58 The selection methods to control for the uniformity of flower sampling from each  
59 registered strain of hemp prepared for harvesting can vary slightly based on a local regulator's  
60 protocol. The samples are then sent to an analytical lab, either operated by the state or individually  
61 contracted, to determine the concentration of cannabinoids in each varietal (strain) of hemp  
62 sampled. Industry or other standard operating procedures for these labs are missing. In addition,  
63 none of the commercial labs we evaluated provided experimental details about the applied methods  
64 or validation data. This may be related to the lack of regulations and reflect a means of maintaining  
65 a competitive advantage in a competitive environment. The lack of validated convention methods  
66 means that generally accepted standards for instruments, calibration, or sampling replicates are  
67 missing. However, in any state, if the test results reveal a total THC concentration below 0.3%,  
68 the farmer is approved to harvest on their listed date. However, if the THC test result is above  
69 0.3% it is considered "hot", and the farmer may have to destroy the entire crop.

70 The federal mandate distinguishes between hemp and marijuana based on plant chemotype,  
71 using a single marker compound (THC), but without establishing a convention method that is "fit  
72 for purpose" for this definition. This is despite the existence of fit-for-purpose chemotype  
73 identification convention methods in the literature (Sarma et al., 2020). The lack of a validated  
74 convention method representing the official standard is particularly problematic because  
75 measurement of the THC concentration involves quantitation at a relatively low level, which poses

76 analytical challenges, especially when performed outside highly controlled laboratory settings.  
77 With limited federal regulation over hemp analytical laboratory accreditation policies or  
78 standardized analysis protocols, the quantitation of cannabinoid composition reported by  
79 commercial hemp testing laboratories has the potential to vary greatly, including for identical  
80 samples. The sources of potential variation extend beyond analytic techniques and include sample  
81 storage upon receipt, homogenization and extraction methods, instrumentation, and calibration  
82 procedures. Collectively, these factors all influence the test results and, thereby, the ultimate  
83 decision about crop validation versus destruction. The development of different analytical methods  
84 to quantify cannabinoids in plant products allows individual laboratories to compete in a growing  
85 market for hemp analysis. However, this practice also interferes with transparency, exacerbates  
86 inter-laboratory variation in analysis results, diminishes the validity of crop regulation, and calls  
87 the overall value of COAs into question.

88         The attention focus on a single marker compound, THC, also raises the question about  
89 options and rationales for a more holistic analysis of the cannabinoid metabolome, which in fact  
90 is practically feasible. Potential approaches including methods for the quantitation of 13 individual  
91 cannabinoids have been compiled by the USP Cannabis Expert Panel (Sarma et al., 2020).  
92 However, with the legal definition of the Controlled Substance Act (CSA) in place, this does still  
93 not address the question of standardization of the analytical methodology used to determine  
94 cannabinoid content, including threshold CBD values. In this context, it should be pointed out that  
95 pharmacopeial approaches worldwide involve the establishment of convention methods, which are  
96 developed via a consensus building process and considered fit-for-purpose. While this approach  
97 provides a more definitive analytical framework, it does not necessarily address the levels of  
98 uncertainty involved in the analyses and are typically not embedded into metrological frameworks

99 by inclusion of primary reference standards (such as NIST benzoic acid PS1) and traceable  
100 certified reference materials (Nelson et al., 2018).

101

## 102 **2. Experimental**

### 103 *2.1 Laboratory survey*

104 A total of 45 laboratories were identified via a Google search of the term “analytical  
105 cannabis testing labs” and contacted about their participation in a research survey of their analytical  
106 methods, prioritizing labs that provided services to regulatory agencies above those used only by  
107 the industry. Of the 45 labs contacted, 11 agreed to participate. One of the participating laboratories  
108 was eliminated because it did not offer hemp testing. The 10 participating laboratories were asked  
109 to extract and analyze three hemp flower samples and to return their cannabinoid potency test  
110 results. Surveyed laboratories were also asked to provide information about their instrumentation,  
111 standards, extraction protocols, and methods of analysis. While all of the participating laboratories  
112 chose to withhold their extraction and analysis protocols, they disclosed the manufacturer and  
113 make of their analytical instrumentation and source of reference standards employed for  
114 calibration.

### 115 *2.2 Preparation*

116 Two strains of hemp, Sample A, a high-CBG chemotype, and Sample B, a high-CBD  
117 chemotype, were cultivated for this survey. Samples from each strain were harvested on the same  
118 day. The samples were prepared from buds removed from the stalks and trimmed of surrounding  
119 leaves. The samples from each strain were collected into a bag and shaken to randomly distribute  
120 flowers collected from individual plants for distribution to the testing facilities. Homogenized  
121 samples were ground using a Spex 2010 Geno/Grinder 115V. Flowers from each sample were

122 added to 50 mL centrifuge tubes along with three steel balls. Each sample was run at 1,000 strokes  
123 per minute for one minute, then manually stirred and visually inspected to ensure all flowers were  
124 ground. The grinding process was repeated at 1,000 strokes per minute for one minute. All ground  
125 flower from each sample was combined in a designated container and mixed again to ensure a  
126 completely homogenized distribution, minimizing variability due to flower selection from one  
127 individual plant or a portion thereof to another given the same strain.

### 128 *2.3 Extraction control experiment*

129 To determine variation in cannabinoid results due to extraction solvents, an internal  
130 analysis was performed using various extraction solvents. Homogenized flowers from Sample B  
131 were extracted nine times using each of the solvents reportedly used by the labs in the survey.  
132 About 200 mg of homogenized flowers was added to each of nine 50 mL polypropylene centrifuge  
133 tubes. The exact mass of Sample B was recorded for each tube, and each sample was extracted  
134 with 20 mL ethanol (3), 20 mL isopropanol (3), or 20 mL 1:1 isopropanol and acetonitrile (3).  
135 Each tube was mixed with a FisherBrand VWR Multi-tube vortexer at speed 9 for 5 minutes. Each  
136 of the tubes was centrifuged in a Q-Sep 3000 Centrifuge 110V for 5 minutes to separate residual  
137 solids from the supernatant. 1.5 mL of the suspended supernatant was removed and syringe-filtered  
138 through a Millex GP 0.22 µm filter to remove solid particulates. 50 µl of the supernatant was added  
139 to a 1.5 mL amber HPLC vial and diluted with 950 µl of the respective extraction solvent. The  
140 samples were analyzed using a Shimadzu LC2030-3D plus with a PDA detector equipped with a  
141 NexLeaf CBX C18 column and mobile phase 0.085% phosphoric acid in acetonitrile. The sample  
142 was compared to calibration standards “Certified Standard-11 Components (CRM) in  
143 Acetonitrile” sourced from Cayman Chemicals. The 250 µg/mL standard mixture was diluted to

144 0.5 ppm, 1 ppm, 5 ppm, 10 ppm, 50 ppm, and 500 ppm ( $R^2 > 0.999$  for each of the 11  
145 cannabinoids).

#### 146 *2.4 Sample B extract preparation*

147 200.4 mg of homogenized Sample B was added to a 50 mL polypropylene centrifuge tube  
148 and extracted with 20 mL ethanol. The mixture was mixed with a FisherBrand VWR Multi-tube  
149 vortex at speed 9 for 5 minutes. The sample was centrifuged in a Q-Sep 3000 Centrifuge 110V for  
150 5 minutes. The suspended supernatant was drawn into a syringe and filtered using a 0.22  $\mu\text{m}$  Millex  
151 GP filter. We sent each surveyed lab 1 mL of the filtered extract in a vial sealed using parafilm  
152 and shipped in insulated, light-proof packaging. Participating laboratories were instructed to dilute  
153 the sample further using ethanol as necessary prior to the cannabinoid potency determination.

154

### 155 **3. Results and discussion**

156 For the survey used in this report, two strains of hemp, Sample A, a high-CBG chemotype,  
157 and Sample B, a high-CBD chemotype, were collected as whole flowers and distributed to  
158 laboratories that agreed to participate in a blind study of their analytical results and a survey of  
159 their testing protocols. The samples were also analyzed in our laboratory to further study the effects  
160 of homogenization and extraction protocols, and compare the results from the labs against a  
161 carefully controlled and transparent sample preparation, calibration, and analytic procedure. The  
162 reported total THC content of Sample A varied among ten surveyed laboratories (Figure 1) with a  
163 mean of 0.11% (dry weight basis), a standard deviation of 0.10%, and three labs returning a non-  
164 detect (ND) result, indicating that total THC content was below the limits of their detection  
165 methods (for the purposes of statistical analysis, ND results were treated as a result of 0%). Total



166 THC/CBD is calculated using the following formulas to take into account the loss of a carboxyl  
167 group during decarboxylation step:

$$168 \quad \text{Total THC} = \Delta^9\text{THC} + (\text{THCa} (0.877)) \text{ and Total CBD} = \text{CBD} + (\text{CBDa} (0.877))$$

169

170 Of the ten surveyed laboratories, one reported a result of 0.29% of THC, a value just below  
171 the legal threshold for crop destruction. The range of reported total THC (including THCA) content  
172 in this sample therefore spans 96.7% of the legally permissible total THC detection range for hemp,  
173 with a relative standard deviation of 95% of the mean. This suggests that the applied analytical  
174 methods for total THC quantitation across surveyed laboratories are not sufficiently precise at the  
175 levels required for the analysis of THC content in hemp. Our own analysis yielded a total THC  
176 content of 0.09%, close to the mean reported by the sample of surveyed laboratories.

177

178

179

180 From harvest of flower samples to sample preparation, homogenization, extraction,  
181 analysis, and quantitation, multiple factors can contribute to the variation in the reported total THC  
182 content, independently of the analytical method used. We probed these potential sources of  
183 variation by sending participating laboratories a homogenized (ground) Sample A, which was  
184 identified to participating laboratories as a third sample, Sample C. Although the plant material  
185 was identical to Sample A, the variation in reported results significantly decreased (standard  
186 deviation  $\sigma = 0.10\%$  in whole flower and  $\sigma = 0.05\%$  in homogenized flower), indicating that, in  
187 addition to potential flower-to-flower variation, different homogenization methods between  
188 laboratories also contributed to significant variation in the quantified total THC content.

189 Sample B was shipped to participating laboratories homogenized using a GenoGrinder. In  
190 this sample, the total THC content measured in our laboratory (0.51%) was higher than that of  
191 Sample A. Again, only the mean of the total THC content reported by the ten participating  
192 laboratories yielded a result similar to control (0.48%), whereas the reported values ranged from  
193 0.27% (compliant) to 0.59% (non-compliant), with a relative standard deviation of 21% of the  
194 mean. Although the relative standard deviation was lower in this sample relative to Sample A, the  
195 standard deviation remained as high as 0.10% dry weight in terms of total THC content).

196 While all external laboratories reported using HPLC with UV-vis photodiode array  
197 detectors, the solvent used to extract flower samples varied: nine laboratories used methanol, one  
198 laboratory a 1:1 mixture of isopropanol and acetonitrile. In our internal reference analysis, ethanol  
199 was employed as the extraction solvent. In an extraction control experiment, nine samples of  
200 homogenized sample B were extracted with either ethanol (3), methanol (3), or  
201 isopropanol/acetonitrile (3). It was found that ethanol yielded the most exhaustive extraction,  
202 regardless of whether only total THC (Table 1) or total cannabinoid content were compared (15.7%  
203  $\pm 0.5$ , 14.3%  $\pm 0.2$ , 15.1%  $\pm 0.8$  for ethanol, methanol, and isopropanol/acetonitrile, respectively).

204 Given the success in reducing analytical variation by pre-homogenizing flower samples,  
205 we anticipated that extracting the homogenized flower and shipping the extract to participating  
206 laboratories would significantly reduce variation. However, the variation in reported total THC  
207 content among participating laboratories increased when pre-extracted samples versus whole  
208 flower samples were shipped to and analyzed by participating laboratories (Sample B  
209 homogenized flower  $\sigma = 0.10\%$  and extracted  $\sigma = 0.12\%$ ).

210 A pre-extracted sample should show the highest degree of homogeneity (lowest variation)  
211 between aliquots sampled by participating laboratories, as it controls for all aspects of sample

212 harvesting and preparation up to analytical method and quantitation. One reason for the observed  
213 variations of results may be that participating laboratories employ sample preparation and analysis  
214 protocols for whole flower samples rather than liquid samples sent from customers. Here, variation  
215 may be due to lack of consistency of liquid sample handling, dilution procedures, and time to  
216 complete the analysis.

217         The outcomes of this survey highlight the potential issues resulting from variation among  
218 laboratories testing THC content. Farmers cultivating hemp strains for medicinal applications,  
219 however, will be interested not only in the THC content reported in COAs, but in the content of  
220 many other cannabinoids quantified in hemp samples. The variation in total cannabinoid content  
221 is shown in Figure 2, where it can be seen that for the whole flower Sample A, reported  
222 cannabinoid content spans a range from 9.8% to 19.4%—a huge variation. This once more  
223 highlights the importance of considering a wider spectrum of cannabinoids when evaluating  
224 cannabis materials (Sarma et al., 2020).

225         In addition to unavoidable inter-laboratory variation, the observed inconsistencies of the  
226 analytical outcomes can be inherent to the method by which cannabinoids are measured: HPLC  
227 with photodiode array detection is a comparative technique that relies on efficient separation,  
228 which in turn depends on many factors such as the specific column and chromatographic  
229 conditions (mobile phase solvents, solvent gradient, flow rate, temperature). To achieve  
230 quantitation, the HPLC chromatogram of a sample is compared to a chemically identical reference  
231 material (“standard”) that is analyzed under identical conditions to establish internal or external  
232 calibration. Provided that multiple calibrants are available, complex mixtures can be separated and  
233 individual components quantified. However, peaks overlap is one major source of error, especially  
234 when analyzing chemically complex mixtures such as Cannabis extracts. For example, similar or

235 fully overlapping retention times under the applied conditions—as is often the case, for instance  
236 with  $\Delta 8$ - vs.  $\Delta 9$ -THC or the *cis* and *trans* isomers — , affect the specificity of the quantitation.  
237 Moreover, the reference materials used for calibration can undergo chemical change (degradation),  
238 which may or may not be captured in both externally and internally calibrated methods. In fact, as  
239 terpenoids, cannabinoids are known to be relatively unstable compounds and commonly change  
240 after exposure to heat, light, or air (not counting the common decarboxylation reaction of the acid  
241 forms).

242           It should be noted that analytical methods are available that are independent of chemically  
243 identical reference materials (calibrants). For example, quantitative nuclear magnetic resonance  
244 (qNMR) has this capability as it represents a (relative) primary analytical technique. Its suitability  
245 for natural product and pharmaceutical analysis is widely acknowledged and the fitness of the  
246 application of quantum mechanics-based qNMR has recently been demonstrated for CBD (Pauli  
247 et al., 2014; Nelson et al., 2020).

248           The laboratories surveyed in this study used reference standards from Restek, Cerilliant,  
249 LGC, and Cayman. While most laboratories employed 11 standards, up to 18 standards were used  
250 to quantify various cannabinoids in hemp samples. Facilities that quantified a larger number of  
251 individual cannabinoids tended to report greater means in total cannabinoid content. However, no  
252 correlation was found between the number of calibration standards and the reported total percent  
253 content quantified across all facilities and all four samples. This kind of inconsistency highlights  
254 the analytical challenges hemp farmers face when evaluating the reliability of COA results and  
255 assessing the value of their crops.

256  
257

258

259 **4. Conclusion**

260 This study represents a preliminary survey of the variation in reported total THC content  
261 among ten commercial hemp testing facilities. While early, the presented evidence strongly  
262 suggests that inconsistencies exist in reported total THC content, which leads to a regulatory  
263 liability. While the total THC content is currently the key legal metric defining whether a crop is  
264 harvestable or must be destroyed, it is not tied to, for example, a convention method that ensures  
265 validity and reproducibility of analytical outcomes, such as the methods found in pharmacopeias.  
266 The present data suggest that total THC content is frequently reported imprecisely, most likely due  
267 to analytical inconsistency of sample preparation and testing methods. Even under the carefully  
268 controlled conditions of the in-house laboratory, the relative standard deviation of total THC  
269 content as measured by HPLC using commercially available calibrants varied between 2% and 7%  
270 of the mean, depending on the extraction protocol employed. This variation is within the range of  
271 what can be expected for the quantitation of a minor (<1%) constituent embedded in a complex  
272 analytical matrix and indicates the intrinsic limitations in peak purity as the likely key factor in  
273 HPLC-UV-based quantitation.

274 These results suggest a significant likelihood of a hemp crop being marked for destruction  
275 due to inaccurate COA reporting – as well as a crop being labeled as compliant despite actually  
276 containing elevated THC levels. To support this burgeoning industry those exposed to the risk of  
277 growing this relatively new crop in the U.S., it would be a step forward to revise enforcement of  
278 COA results such that they account for the variation in reported total THC content, introduce  
279 methodology that establishes a reproducible linkage with metrological reference materials, and  
280 eliminate the inherent variability of results from different analytical methods. To do this, however,  
281 several factors would need to be carefully considered. The current regulatory specifications are

282 simple numbers that do not include measurement uncertainties. Determining the threshold values  
283 may have involved accounting for measurement uncertainty, but the values do not express that.  
284 In pharmacopeial monographs and standards, general rules exist about precision and accuracy, for  
285 example for the difference between 0.3% and 0.30%. Threshold values such as NMT 0.3%,  
286 however, are agnostic to statistics as they are expressed with only one significant number. It is  
287 always good to define the specifications of an analytical method to avoid this confusion, for  
288 example by clarifying that threshold values or ranges include three significant numbers, two true  
289 and one uncertain, as is common in analytical chemistry (Eurachem, 2012). This will also allow  
290 testing labs to demonstrate their fitness for analytical purposes. Considering our results, from the  
291 viewpoint of statistics alone, it may be adequate to introduce ranges of two standard deviations of  
292 the legal limit when defining the thresholds that determine the legal designation of a crop as hemp  
293 vs. marijuana.

294         Until these points are addressed, the definition of hemp based on an arbitrary number with  
295 one significant figure as upper boundary (“0.3%”) of total THC content remains flawed, due to the  
296 demonstrated variability in the reported measurements of that value and the difficulty and cost of  
297 making the measurement for each crop. It should also be borne in mind that genotyping, rather  
298 than chemotyping, offers a valuable approach to the distinction of hemp from marijuana. Legal  
299 definitions that consider the existing analytical evidence will help protect hemp farming from the  
300 undue liability of misrepresented or inaccurate strain identification and flawed chemical analysis,  
301 and will foster the rational development of hemp crops with expanded utility by means of specific  
302 chemotype.

303

304

305

306 **5. Captions of figures**

307

308 Figure 1. Total THC content distributions as reported by ten participating commercial hemp  
309 analysis laboratories in the U.S.

310

311 Figure 2. Total cannabinoid concentration reported (top) and a comparison between total  
312 cannabinoids reported and number of standards used in quantitation (bottom).

313

314 **References**

315 Bridgeman, M.B., and Abazia, D. 2017. Medical Cannabis: History, Pharmacology, and

316 Implications for Acute Care Settings. *Pharmacy and Therapeutics*, 42(3), 180-188.

317 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312634/>

318 California Industrial Hemp Law and Regulations. CA Code of Regulations Title 3, Div. 4, Ch. 8,

319 Art. 3. January 19, 2021.

320 [https://www.cdfa.ca.gov/plant/industrialhemp/docs/CaliforniaIndustrialHempLawandReg](https://www.cdfa.ca.gov/plant/industrialhemp/docs/CaliforniaIndustrialHempLawandRegulations.pdf)

321 [ulations.pdf](https://www.cdfa.ca.gov/plant/industrialhemp/docs/CaliforniaIndustrialHempLawandRegulations.pdf)

322 De Meijer, E.P.M., Bagatta, M., Carboni, A., Crucciti, P., Moliterni, V.M.C., Ranalli, P.,

323 Mandolino, G. 2003. The inheritance of chemical phenotype in *Cannabis sativa* L.

324 *Genetics*, 163, 335-346. <https://doi.org/10.1093/genetics/163.1.335>

325 Ellison, S.L. and Williams, A., 2012. Quantifying uncertainty in analytical measurement.

326 Eurachem/CITAC.

327 Sawler, J., Stout, J.M., Gardner, K.M., Hudson, D., Vidmar, J., Butler, L., Page, J.E.  
328 2015. PLOS ONE. 10, 1-9. <https://doi.org/10.1371/journal.pone.0133292>

329 Small, E., and Marcus, D. 2002. Hemp: A New Crop with New Uses for North America. Trends  
330 in New Crops and New Uses, ed. J. Janick and A. Whipkey, Alexandria, VA. American  
331 Society for Horticultural Science Press: 284-326.  
332 <https://www.hort.purdue.edu/newcrop/ncnu02/v5-284.html>

333 Nelson, M. A.; Waters, J. F.; Toman, B.; Lang, B. E.; Rück, A.; Breitruck, K.; Obkircher, M.;  
334 Windust, A.; Lipka, K. A. 2018. A New Realization of SI for Organic Chemical  
335 Measurement: NIST PS1 Primary Standard for Quantitative NMR (Benzoic Acid).  
336 Analytical Chemistry. 90, 10510-10517. <https://doi.org/10.1021/acs.analchem.8b02575>

337 Nelson, K.M., Bisson, J., Singh, G., Graham, J.G., Chen, S.N., Friesen, J.B., Dahlin, J.L.,  
338 Niemitz, M., Walters, M.A. and Pauli, G.F., 2020. The essential medicinal chemistry of  
339 cannabidiol (CBD). Journal of medicinal chemistry, 63(21), 12137-12155.  
340 <https://doi.org/10.1021/acs.jmedchem.0c00724>

341 Pauli, G.F., Chen, S.N., Simmler, C., Lankin, D.C., Gödecke, T., Jaki, B.U., Friesen, J.B.,  
342 McAlpine, J.B. and Napolitano, J.G., 2014. Importance of purity evaluation and the  
343 potential of quantitative <sup>1</sup>H NMR as a purity assay: miniperspective. Journal of  
344 medicinal chemistry, 57(22), 9220-9231. <https://doi.org/10.1021/jm500734a>


345 Sarma, N. D., Waye, A., ElSohly, M. A., Brown, P. N., Elzinga, S., Johnson, H. E., H.E., Marles,  
346 R.J., Melanson, J.E., Russo, E., Deyton, L. and Hudalla, C., Vrdoljak, G.A., Wurzer, J.H.,  
347 Khan, I.A., Kim, Nam-Cheol & Giancaspro, G. I. 2020. Cannabis inflorescence for  
348 medical purposes: USP considerations for quality attributes. Journal of natural products,  
349 83(4), 1334-1351. <https://doi.org/10.1021/acs.jnatprod.9b01200>



350 Small, E. and Cronquist, A. 1976. A practical and natural taxonomy for Cannabis. Taxon, 25:  
351 405-435. <https://doi.org/10.2307/1220524>


352 USDA Agricultural Marketing Service. 2019. Establishment of a domestic hemp production  
353 program. Fed. Reg., 84(211), 58522-58564.

354




355 **Figure 1.** Total THC content distributions as reported by ten participating commercial hemp  
356 analysis laboratories in the U.S.  
357

358



359



360

361 **Figure 2.** Total cannabinoid concentration reported (top) and a comparison between total  
 362 cannabinoids reported and number of standards used in quantitation (bottom).

363

364

365 **Table 1.** Total THC content measured in identical samples extracted with various solvents

	Ethanol	Methanol	Isopropanol/acetonitrile (1:1)
Sample 1	0.520	0.445	0.45
Sample 2	0.507	0.463	0.51
Sample 3	0.502	0.459	0.47
Average	0.510 ± .007	0.456 ± .008	0.48 ± .03

366